scholarly journals Recent advances in personalized lung cancer medicine

2014 ◽  
Vol 11 (3) ◽  
pp. 309-321 ◽  
Author(s):  
Ross A Okimoto ◽  
Trever G Bivona
Keyword(s):  
Lung Cancer ◽  
Recent Advances ◽  
Cancer Medicine

scholarly journals Recent advances in the management of non-small cell lung cancer

F1000Research ◽  
2017 ◽  
Vol 6 ◽  
pp. 2110 ◽  
Author(s):  
Samira Shojaee ◽  
Patrick Nana-Sinkam
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Surgical Approaches ◽  
Small Cell Lung ◽  
Cancer Management ◽  
Recent Advances ◽  
Improved Outcomes ◽  
Significant Step

Lung cancer is the number one cause of cancer-related death in both men and women. However, over the last few years, we have witnessed improved outcomes that are largely attributable to early detection, increased efforts in tobacco control, improved surgical approaches, and the development of novel targeted therapies. Currently, there are several novel therapies in clinical practice, including those targeting actionable mutations and more recently immunotherapeutic agents. Immunotherapy represents the most significant step forward in eradicating this deadly disease. Given the ever-changing landscape of lung cancer management, here we present an overview of the most recent advances in the management of non-small cell lung cancer.

scholarly journals Recent advances in the management of lung cancer

2018 ◽  
Vol 18 (Suppl 2) ◽  
pp. s41-s46 ◽  
Author(s):  
Gavin S Jones ◽  
David R Baldwin
Keyword(s):  
Lung Cancer ◽  
Recent Advances

Recent advances in radiotherapy for lung cancer

2012 ◽  
pp. 119-128
Author(s):  
Dirk K. M. De Ruysscher ◽  
José S.A. Belderbos
Keyword(s):  
Lung Cancer ◽  
Recent Advances

Lessons Learned From Lung Cancer Genomics: The Emerging Concept of Individualized Diagnostics and Treatment

2013 ◽  
Vol 31 (15) ◽  
pp. 1858-1865 ◽  
Author(s):  
Reinhard Buettner ◽  
Jürgen Wolf ◽  
Roman K. Thomas
Keyword(s):  
Lung Cancer ◽  
Mechanism Of Action ◽  
Trial Design ◽  
Cancer Genomics ◽  
Lung Tumor ◽  
Genetic Alterations ◽  
Lessons Learned ◽  
Cancer Medicine ◽  
Egfr Mutant ◽  
Preclinical Work

The advent of novel therapeutics that specifically target signaling pathways activated by genetic alterations has revolutionized the way patients with lung cancer are treated. Although only few and largely ineffective chemotherapeutic regimens were available 10 years ago, a lung tumor diagnosed today requires extensive pathologic subtyping and diagnosis of genome alterations to afford more effective treatment (eg, in EGFR-mutant adenocarcinoma). This change of paradigm has several profound implications, ranging from preclinical work on the mechanism of action to a novel, more biologically oriented taxonomy and from genome diagnostics to trial design. Here, we have summarized these developments into six conceptual paradigms that illustrate the transition from empirical cancer medicine to mechanistically based individualized oncology.

Recent advances in the treatment of non-small cell lung cancer

1996 ◽  
Vol 7 (4) ◽  
pp. 363-385 ◽  
Author(s):  
Glenwood D. Goss ◽  
Simone Dahrouge ◽  
Catherine A. Lochrin
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Recent Advances
Sign in / Sign up

Export Citation Format

Share Document